Vesugen

Vesugen is a short synthetic peptide built from three amino acids, lysine, glutamic acid and aspartic acid, giving the sequence Lys-Glu-Asp ^[1][4]. It is one of the peptide bioregulators, sometimes called ultrashort peptides, developed at the Saint Petersburg Institute of Bioregulation and Gerontology by Vladimir Khavinson and colleagues ^[5][6]. In this framework Vesugen is designated a vascular peptide, meant to mirror the regulatory activity attributed to the tissues of the blood-vessel wall; the same tripeptide sequence appears in the research literature under the laboratory code T-38 ^[1][4].

Like other members of the family, Vesugen emerged from a long program of Russian research that began with complex peptide extracts of animal organs and progressed to short, defined peptides intended to carry tissue-specific effects ^[5]. The vascular peptide was created to target the endothelium, the inner lining of blood vessels, whose dysfunction is central to atherosclerosis and other age-related vascular disease ^[1][3].

Reported studies have centered on the blood vessels and on aging ^[1][3]. In laboratory work the tripeptide has been described as vasoprotective, said to renew vascular cells in culture and to lower markers linked to atherosclerotic plaque formation ^[1]. Small clinical reports from its originators have examined it in older adults, including its use in chronic arterial insufficiency of the legs and in vasculogenic erectile dysfunction arising from atherosclerosis, as well as broader assessments of biological aging ^[2][3]. Related experiments describe the same Lys-Glu-Asp peptide affecting tissue regeneration in models of accelerated aging ^[4].

Vesugen and related peptide bioregulators are used and sold mainly in Russia and some neighboring countries as bioregulator preparations, and they are not approved as medicines by regulators such as the U.S. Food and Drug Administration or the European Medicines Agency ^[5]. The available evidence consists largely of small studies and reviews from a narrow group of laboratories, frequently published in Russian, so the results are preliminary and have not been widely confirmed by independent researchers. Vesugen is generally encountered as a research peptide rather than an established treatment.

The source literature does not flag much, and short bioregulator peptides like KED generally come across as low toxicity and well tolerated, without the hormonal or immune baggage of larger peptides. The honest caveat matters more here than usual though; nearly all of the data come from Khavinson-affiliated labs, mostly in cell culture, with little independent Western replication and no strong randomized human outcome trials. It is an experimental research peptide, not an approved medicine, so purity of what is actually sold is unverified, and standard injection site risks apply if you go that route. Best treated as an interesting bioregulator to watch rather than a proven therapy.